Incubate’s John Stanford on why MFN’s first casualty is the moonshot — and why cancer, Alzheimer’s, and rare disease bear the cost.
|Articles|July 25, 2019
Talking with Peter Barschdorff Vice President, Commercial Insights, GSK
Associate Editor, Christen Harm talks with Peter Barschdorff, Vice President, Commercial Insights, GSK , at the 2019 18th Annual eyeforpharma Philadelphia Conference, Expo & Awards.
Advertisement
Associate Editor, Christen Harm talks with Peter Barschdorff, Vice President, Commercial Insights, GSK , at the 2019 18th Annual eyeforpharma Philadelphia Conference, Expo & Awards.
Advertisement
Related to this article
Incubate’s John Stanford on why MFN reduces pharma’s appetite for biotech acquisitions — and why that cedes ground to China.
Incubate’s John Stanford on why MFN deals are voluntary in name only — and why the leverage looks a lot like the IRA’s 95% excise tax.
Incubate’s John Stanford on why MFN hits mid-sized pharma harder — fewer products to absorb margin hits and less access to cheap capital.
Fox Rothschild's Marc Wagner on why domestic manufacturing reduces drug shortage risk — and why FDA inspection efficiency is as important as supply chain resilience.
Fox Rothschild's Marc Wagner on how 503A pharmacies and 503B outsourcing facilities fill drug supply gaps — from COVID injectables to GLP-1s.
Advertisement
Advertisement
Trending on PharmExec
1
Roundup: Gilead Acquires Oral IL-23R Inhibitor From PepStar for $1.275 Billion, Zymeworks Licenses DLL3-Targeting T Cell Engager to Roche
2
Treasury Proposes Rules Adding Biotechnology to Outbound Investment Security Program
3
FDA Approves Hibsago (Bepirovirsen) for Chronic Hepatitis B
4
MFN Is an Offer Pharma Can’t Refuse
5